Dementia is one of the most common and important aspects of Parkinson's disease and has
consequences for patients and caregivers, and has health-related costs. Mild cognitive …

Background Parkinson's disease is associated with an increased incidence of cognitive
impairment and dementia. Predicting who is at risk of cognitive decline early in the disease …

Parkinson's disease (PD) has long been considered predominantly a motor disorder.
However, its frequent association with dementia, which contributes significantly to the …

Neurodegeneration in Parkinson's disease starts years before a clinical diagnosis can be
reliably made. The prediagnostic phase of the disease offers a window of opportunity in …

Cognitive impairment in patients with Parkinson's disease is gaining increased clinical
significance owing to the relative success of therapeutic approaches to the motor symptoms …

The clinical diagnosis of Parkinson's disease rests on the identification of the characteristics
related to dopamine deficiency that are a consequence of degeneration of the substantia …

Neuromodulatory or even neuroprotective therapy could soon be available for Parkinson's
disease (PD), raising the question of how we should define and measure disease …

Recent findings question our present understanding of Parkinson's disease and suggest that
new research criteria for the diagnosis of Parkinson's disease are needed, similar to those …

Objective To assess the effect of rivastigmine in patients with mild cognitive impairment
(MCI) on the time to clinical diagnosis of Alzheimer's disease (AD) and the rate of cognitive …

Background The use of cholinesterase inhibitors to correct the cholinergic deficit in patients
with mild to moderate Alzheimer's disease (AD) is well established. However, the treatment …